Kessler Paul D. 4
4 · NABI BIOPHARMACEUTICALS · Filed May 18, 2011
Insider Transaction Report
Form 4
Kessler Paul D.
SVP Clinical, Med. & Reg.; CMO
Transactions
- Sale
Common Stock
2011-05-16$5.53/sh−7,500$41,447→ 115,171 total - Sale
Common Stock
2011-05-16$5.48/sh−4,876$26,712→ 110,295 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.